Celsion

CLSN NASDAQ
2.140
-0.010
-0.47%
已收盘, 16:00 05/17 EDT
开盘
2.240
昨收
2.150
最高
2.240
最低
2.100
成交量
8.70万
成交均量(3M)
17.06万
52周最高
3.480
52周最低
1.350
换手率
0.45%
市值
4,186.27万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Celsion CLSN股票价格,Celsion股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
展开 >

最近浏览

名称
价格
涨跌幅